Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

November 8, 2016November 8, 2016

Can Certain Odors Worsen Airway Diseases? Researchers Think So

Asthma, Chronic Bronchitis, COPD, Emphysema, News

Olfactory receptors, a group of proteins that are activated by certain odors in the nose, can also be found in bronchi cells, where they regulate the way these cells work, ... Read more

November 4, 2016November 4, 2016

Preclinical Studies Show Promise for Cystic Fibrosis Therapy in Early Clinical Testing

Cystic Fibrosis, News

SPX-101, an investigational drug for the treatment of cystic fibrosis (CF) being developed by Spyryx Biosciences, has shown to be a safe, stable, and efficient therapy in animal models of the ... Read more

October 11, 2016October 11, 2016

First Patient Enrolled in Phase 3 Trial Assessing Bardoxolone Methyl to Treat CTD-PAH

News, Pulmonary Hypertension

Reata Pharmaceuticals announced the enrollment of the first patient in its Phase 3 CATALYST study (NCT02657356) that will evaluate the effectiveness and safety of bardoxolone methyl in patients with connective ... Read more

September 21, 2016September 21, 2016

New Data Supports Esbriet as Safe, Effective Treatment for IPF Patients

Idiopathic Pulmonary Fibrosis, News

Positive results from four analyses based on clinical trials developed by Roche to evaluate the effectiveness of Esbriet (pirfenidone), an oral antifibrotic medication approved by the U.S. Food and Drug ... Read more

August 8, 2016August 8, 2016

Early Treatment with Esbriet Can Help Slow IPF Progression, Study Finds

Idiopathic Pulmonary Fibrosis, News

Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease, and patients have very few options once the disease seriously progresses. Now, a study from the University of Turin, Italy, suggests ... Read more